Chemoprevention of benzo(a)pyrene-induced colon polyps in ApcMin mice by resveratrol

Journal of Nutritional Biochemistry

Volumn 24, Issue 4, 2013, Pages 713-724

  Huderson, Ashley C ^a   Myers, Jeremy N ^a   Niaz, Mohammad S ^a   Washington, Mary K ^b   Ramesh, Aramandla ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ApcMin mouse; Benzo(a)pyrene; Colon carcinogenesis; Polycyclic aromatic hydrocarbons; Resveratrol

Indexed keywords

APC PROTEIN; ARACHIS OIL; BENZO[A]PYRENE; RESVERATROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CARCINOGENESIS; COLON POLYP; CONTROLLED STUDY; DYSPLASIA; FEEDING; HISTOPATHOLOGY; JEJUNUM; LIVER; MALE; MOUSE; NONHUMAN;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BENZO(A)PYRENE; CELL CYCLE; COLONIC NEOPLASMS; COLONIC POLYPS; MALE; MICE; STILBENES;

ARACHIS HYPOGAEA; MUS;

EID: 84875071965     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.04.005     Document Type: Article

References (96)

1. Chu K.C., Tarone R.E., Chow W.H., Hankey B.F., Ries L.A. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst 1994, 86:997-1006.
2. World Cancer Fund and the American Institute for Cancer Research Food, nutrition and the prevention of cancer: a global perspective 1997, American Institute for Cancer Research, Washington.
3. IPCS Environmental health criteria 202: selected non-heterocyclic polycyclic aromatic hydrocarbons 1998, International Programme on Chemical Safety, World Health Organization, Lyon, France.
4. Kazerouni N., Sinha R., Hsu C.-H., Greenberg A., Rothman N. Analysis of 200 food items for benzo(a)pyrene and estimation of its intake in an epidemiologic study. Food Chem Toxicol 2001, 39:423-436.
5. Ramesh A., Walker S.A., Hood D.B., Guillen M.D., Schneider K., Weyand E.H. Bioavailability and risk assessment of orally ingested polycyclic aromatic hydrocarbons. Int J Toxicol 2004, 23:301-333.
6. Diggs D.L., Huderson A.C., Harris K.L., Myers J.N., Banks L.D., Rekhadevi P.V., et al. Polycyclic aromatic hydrocarbons and digestive tract cancers: a perspective. Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2011, 29:1-34.
7. Russo G.L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 2007, 74:533-544.
8. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009, 2:409-418.
9. Glade M.J. Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research. Nutrition 1999, 15:523-526.
10. Kawajiri K., Kobayashi Y., Ohtake F., Ikuta T., Matsushima Y., Mimura J., et al. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci U S A 2009, 106:13481-13486.
11. Romagnolo D.F., Degner S.C., Selmin O. Aryl hydrocarbon receptor-mediated carcinogenesis and modulation by dietary xenobiotic and natural ligands. Bioactive compounds and cancer-nutrition & health 2010, 761-782. part 4.
12. Pezzuto J.M. Resveratrol as an inhibitor of carcinogenesis. Pharmaceut Biol 2008, 46:443-573.
13. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
14. Half E., Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 2009, 10:211-219.
15. Lubet R.A., Green J., Steele V.E., You M. Potential use of transgenic mice in chemoprevention studies. Cancer chemoprevention, volume 2: strategies for cancer prevention 2005, 47-55. Humana Press, Totowa, New Jersey. G.J. Kelloff, E.T. Hawk, C.C. Sigman (Eds.).
16. Kohler E.M., Derungs A., Daum G., Behrens J., Schneikert J. Functional definition of the mutation cluster region of adenomatous polyposis coli in colorectal tumours. Hum Mol Genet 2008, 17:1978-1987.
17. Iwamoto M., Ahnen D.J., Franklin W.A., Maltzman T.H. Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 2000, 21:1935-1940.
18. Lipkin M., Lamprecht S.A. Modeling of human cancer in mice for chemoprevention studies. Cancer chemoprevention, volume 2: strategies for cancer prevention 2005, 57-68. Humana Press, Totowa, New Jersey. G.J. Kelloff, E.T. Hawk, C.C. Sigman (Eds.).
19. Radtke F., Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005, 307:1904-1909.
20. NIH Guidelines for the laboratory use of chemical carcinogens 1981, NIH Publication No. SI-2385, National Institutes of Health, US Government Printing Office, Washington D.C.
21. Hattemer-Frey H.A., Travis C.C. Benzo(a)pyrene: environmental partitioning and human exposure. Toxicol Ind Hlth 1991, 7:141-157.
22. Falco G., Domingo J.L., Llobet J.M., Teixido C., Muller L. Polycyclic aromatic hydrocarbons in foods: human exposure through the diet in Catalonia, Spain. J Food Prot 2003, 60:2325-2331.
23. De Vos R.H., van Dokkum A., Schouten A., deJong-Berkhout P. Polycyclic aromatic hydrocarbons in Dutch total diet samples (1984-1986). Food Chem Toxicol 1990, 28:263-268.
24. Wang Y., Catana F., Yang Y., Roderick R., van Breeman R.B. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 2002, 50:431-435.
25. Ruehl-Fehlert C., Kittel B., Moraweitz G., Deslex P., Keenan C., Mahrt C.R., et al. Revised guides for organ sampling and trimming in rats and mice-part 1. Exp Toxic Pathol 2003, 55:91-106.
26. Boivin G.P., Washington K., Yang K., Ward J.M., Pretlow T.P., Russell R., et al. Pathology of genetically engineered mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003, 124:762-777.
27. Schneider Y., Duranton B., Gosse F., Schleiffer R., Seiler N., Raul F. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 2001, 39:102-107.
28. Tessitore L., David A., Sarotto I., Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax p21 expression. Carcinogenesis 2000, 21:1619-1622.
29. Walter A., Etienne-Selloum N., Brasse D., Khallouf H., Bronner A., Rio M.C., et al. Intake of grape-derived polyphenols reduces C26 tumor growth by inhibiting angiogenesis and inducing apoptosis. FASEB J 2010, 24:3360-3369.
30. Alfaras I., Juan M.E., Planas J.M. trans-Resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. J Agric Food Chem 2010, 58:8104-8110.
31. Chiou Y.S., Tsai M.L., Wang Y.J., Cheng A.C., Lai W.M., Badmaev V., et al. Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice. J Agric Food Chem 2010, 58:8833-8841.
32. Paul S., DeCastro A.J., Lee H.J., Smolarek A.K., So J.Y., Simi B., et al. Dietary intake of pterostilbene, a constituent of blueberries, inhibits the beta-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis 2010, 31:1272-1278.
33. Sengottuvelan M., Viswanathan P., Nalini N. Chemopreventive effect of trans-resveratrol-a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon. Carcinogenesis 2006, 27:1038-1046.
34. Zhang X., Anderson J., Kalshik R.S., Dwivedi C. Effects of resveratrol an important component of red wine on intestinal cancer development. International Journal of Wine Research 2009, 1:147-153.
35. Hecht S.S., Kenney P.M., Wang M., Trushin N., Agarwal S., Rao A.V., et al. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo(a)pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 1999, 137:123-130.
36. Min/+mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 2005, 115:194-201.
37. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004, 287:G7-G17.
38. Cui X., Jin Y., Hofseth A.B., Pena E., Habiger J., Chumanevich A., et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res 2010, 3:549-555.
39. Li H., Wu W.K., Zheng Z., Che C.T., Yu L., Li Z.J., et al. 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. B. J Pharmacol 2010, 160:1352-1361.
40. Ziegler C.C., Rainwater L., Whelan J., McEntee M.F. Dietary resveratrol does not affect intestinal tumorigenesis in Apc (Min/+) mice. J Nutr 2004, 134:5-10.
41. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011, 1215:9-15.
42. Delmas D., Lançon A., Colin D., Jannin B., Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 2006, 7:423-442.
43. Vitrac X., Desmoulière A., Brouillaud B., Krisa S., Deffieux G., Barthe N., et al. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 2003, 72:2219-2233.
44. Sale S., Verschoyle R.D., Boocock D., Jones D.J., Wilsher N., Ruparelia K.C., et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer 2004, 90:736-744.
45. Andlauer W., Kolb J., Siebert K., Fürst P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res 2000, 26:47-55.
46. Soleas G.J., Angelini M., Grass L., Diamandis E.P., Goldberg D.M. Absorption of trans-resveratrol in rats. Methods Enzymol 2001, 335:145-154.
47. Azorín-Ortuño M., Yáñez-Gascón M.J., Vallejo F., Pallarés F.J., Larrosa M., Lucas R., et al. Metabolites and tissue distribution of resveratrol in the pig. Mol Nutr Food Res 2011, 55:1154-1168.
48. Brown V.A., Patel K.R., Viskaduraki M., Crowell J.A., Perloff M., Booth T.D., et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010, 70:9003-9011.
49. La Porte C., Voduc N., Zhang G., Seguin I., Tardiff D., Singhal N., et al. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010, 49:449-454.
50. Stoner G.D., Morse M.A., Kelloff G.J. Perspectives in cancer chemoprevention. Environ Health Perspect 1997, 105(Suppl. 4):945-954.
51. Ndiaye M., Kumar R., Ahmad N. Resveratrol in cancer management: where are we and where we go from here?. Ann N Y Acad Sci 2011, 1215:144-149.
52. Berge G., Øvrebø S., Eilertsen E., Haugen A., Mollerup S. Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene. Br J Cancer 2004, 91:1380-1383.
53. Zhang M.A., Chen F.H., Huang Z.Y., Zhang X.C. Elaidic acid enhanced the simultaneous neurotoxicity attributable to the cerebral pathological lesion resulted from oxidative damages induced by acrylamide and benzo(a)pyrene. Toxicol Ind Health 2011, 27:661-672.
54. Qamar W., Khan A.Q., Khan R., Lateef A., Tahir M., Rehman M.U., et al. Benzo(a)pyrene-induced pulmonary inflammation, edema, surfactant dysfunction, and injuries in rats: alleviation by farnesol. Exp Lung Res 2012, 38:19-27.
55. de la Lastra C.A., Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007, 35:1156-1160.
56. Katdare M., Osborne M.P., Telang N.T. Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. Oncol Rep 1998, 5:311-315.
57. Goldsworthy T.L., Fransson-Steen R. Quantitation of the cancer process in C57BL/6J, B6C3F1 and C3H/HeJ mice. Toxicol Pathol 2002, 30:97-105.
58. Solhaug A., Øvrebø S., Mollerup S., Låg M., Schwarze P.E., Nesnow S., et al. Role of cell signaling in B[a]P-induced apoptosis: characterization of unspecific effects of cell signaling inhibitors and apoptotic effects of B[a]P metabolites. Chem Biol Interact 2005, 151:101-119.
59. Asensi M., Medina I., Ortega A., Carretero J., Baño M.C., Obrador E., et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002, 33:387-398.
60. Das S., Ng K.Y. Impact of glutaraldehyde on in vivo colon-specific release of resveratrol from biodegradable pectin-based formulation. J Pharm Sci 2010, 99:4903-4916.
61. Vanamala J., Reddivari L., Radhakrishnan S., Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010, 10:238.
62. Fang W.F., Strobel H.W. Effects of cyclophosphamide and polycyclic aromatic hydrocarbons on cell growth and mixed-function oxidase activity in a human colon tumor cell line. Cancer Res 1982, 42:3676-3681.
63. Herbst U., Fuchs J.I., Teubner W., Steinberg P. Malignant transformation of human colon epithelial cells by benzo[c]phenanthrene dihydrodiolepoxides as well as 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Toxicol Appl Pharmacol 2006, 212:136-145.
64. Audebert M., Riu A., Jacques C., Hillenweck A., Jamin E.L., Zalko D., et al. Use of the γH2AX assay for assessing the genotoxicity of polycyclic aromatic hydrocarbons in human cell lines. Toxicol Lett 2010, 199:182-192.
65. Wolter F., Akoglu B., Clausnitzer A., Stein J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 2001, 131:2197-2203.
66. Majumdar A.P., Banerjee S., Nautiyal J., Patel B.B., Patel V., Du J., et al. Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr Cancer 2009, 61:544-553.
67. Sale S., Fong I.L., de Giovanni C., Landuzzi L., Brown K., Steward W.P., et al. APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the Apc(Min) mouse model in vivo. Eur J Cancer 2009, 45:2731-2735.
68. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
69. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
70. Bhat K.P., Pezzuto J.M. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 2002, 957:210-229.
71. Tan A.C., Konczak I., Sze D.M., Ramzan I. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr Cancer 2011, 63:495-505.
72. Ito T., Akao Y., Yi H., Ohguchi K., Matsumoto K., Tanaka T., et al. Antitumor effect of resveratrol oligomers against human cancer cell lines and the molecular mechanism of apoptosis induced by vaticanol C. Carcinogenesis 2003, 24:1489-1497.
73. Martín A.R., Villegas I., La Casa C., de la Lastra C.A. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004, 67:1399-1410.
74. Romier B., Schneider Y.J., Larondelle Y., During A. Dietary polyphenols can modulate the intestinal inflammatory response. Nutr Rev 2009, 67:363-378.
75. Berge G., Øvrebø S., Botnen I.V., Hewer A., Phillips D.H., Haugen A., et al. Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cells. Br J Cancer 2004, 91:333-338.
76. Revel A., Raanani H., Younglai E., Xu J., Rogers I., Han R., et al. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 2003, 23:255-261.
77. Khalil A., Villard P.H., Dao M.A., Burcelin R., Champion S., Fouchier F., et al. Polycyclic aromatic hydrocarbons potentiate high-fat diet effects on intestinal inflammation. Toxicol Lett 2010, 196:161-167.
78. Min mouse exposed to benzo(a)pyrene. Toxicol Pathol 2009, 37:938-946.
79. Larrosa M., Tomé-Carneiro J., Yáñez-Gascón M.J., Alcántara D., Selma M.V., Beltrán D., et al. Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents. J Med Chem 2010, 53:7365-7376.
80. Blagosklonny M.V., Pardee A.B. The restriction point of the cell cycle. Cell Cycle 2002, 1:103-110.
81. Norbury C.J. The cancer cell cycle. Introduction to the cellular and molecular biology of cancer 2005, 156-157. Oxford University Press. 4th edition. M.A. Knowles, P.J. Selby (Eds.).
82. Weiss R.S., Leder P., Vaziri C. Critical role for mouse Hus1 in an S-phase DNA damage cell cycle checkpoint. Mol Cell Biol 2003, 23:791-803.
83. Khan Q.A., Anderson L.M. Hydrocarbon carcinogens evade cellular defense mechanism of G1 arrest in nontransformed and malignant lung cell lines. Toxicol Appl Pharmacol 2001, 173:105-113.
84. Wei W., Li X.F., Li X.N., Chen X.M., Liu A.L., Lu W.Q. Oxidative stress and cell-cycle change induced by coexposed PCB126 and benzo(a) pyrene to human hepatoma (HepG2) cells. Environ Toxicol 2010.
85. Ko C.B., Kim S.J., Park C., Kim B.R., Shin C.H., Choi S., et al. Benzo(a)pyrene-induced apoptotic death of mouse hepatoma Hepa1c1c7 cells via activation of intrinsic caspase cascade and mitochondrial dysfunction. Toxicology 2004, 199:35-46.
86. Jeffy B.D., Chen E.J., Gudas J.M., Romagnolo D.F. Disruption of cell cycle kinetics by benzo[a]pyrene: inverse expression patterns of BRCA-1 and p53 in MCF-7 cells arrested in S and G2. Neoplasia 2000, 2:460-470.
87. Chramostová K., Vondrácek J., Sindlerová L., Vojtesek B., Kozubík A., Machala M. Polycyclic aromatic hydrocarbons modulate cell proliferation in rat hepatic epithelial stem-like WB-F344 cells. Toxicol Appl Pharmacol 2004, 196:136-148.
88. Ahmad N., Adhami V.M., Afaq F., Feyes D.K., Mukhtar H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001, 7:1466-1473.
89. Park J.W., Choi Y.J., Jang M.A., Lee Y.S., Jun D.Y., Suh S.I., et al. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett 2001, 163:43-49.
90. Bai Y., Mao Q.Q., Qin J., Zheng X.Y., Wang Y.B., Yang K., et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 2010, 101:488-493.
91. Schneider Y., Vincent F., Duranton B., Badolo L., Gossé F., Bergmann C., et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 2000, 158:85-91.
92. Kim Y.A., Choi B.T., Lee Y.T., Park D.I., Rhee S.H., Park K.Y., et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep 2004, 11:441-446.
93. Whyte L., Huang Y.Y., Torres K., Mehta R.G. Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res 2007, 67:12007-12017.
94. Bartek J., Lukas C., Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004, 5:792-804.
95. Norbury C.J., Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004, 23:2797-2808.
96. Hsieh T., Halicka D., Lu X., Kunicki J., Guo J., Darzynkiewicz Z., et al. Effects of resveratrol on the G(0)-G(1) transition and cell cycle progression of mitogenically stimulated human lymphocytes. Biochem Biophys Res Commun 2002, 297:1311-1317.